The early immune response to HIV-1 infection is likely to be an important factor in
determining the clinical course of disease. Recent data indicate that the HIV-1 quasispecies …

The development of a safe and effective human immunodeficiency virus (HIV)-1 vaccine is a
critically important global health priority. Despite recent advances in our understanding of …

The acquired immunodeficiency syndrome (AIDS)-causing lentiviruses human
immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) effectively evade …

Background Observational data and non-human primate challenge studies suggest that cell-
mediated immune responses might provide control of HIV replication. The Step Study …

Developing an immunogen that elicits broadly neutralizing antibodies (bNAbs) is an elusive
but important goal of HIV vaccine research, especially after the recent failure of the leading T …

The recent failure of the T-cell-based HIV vaccine trial led by Merck & Co., Inc. prompts the
urgent need to refocus on the question of which T-cell responses are required to control HIV …

The world of human immunodeficiency virus (HIV) vaccines has suffered a baffling setback.
The first trial of a vaccine designed to elicit strong cellular immunity has shown no protection …

The membrane-proximal external region (MPER) of HIV-1, located at the C terminus of the
gp41 ectodomain, is conserved and crucial for viral fusion. Three broadly neutralizing …

Abstract Background. The Step Study tested whether an adenovirus serotype 5 (Ad5)–
vectored human immunodeficiency virus (HIV) vaccine could prevent HIV acquisition and/or …

Induction of broadly cross-reactive neutralizing antibodies (NAb) is an important goal for a
prophylactic human immunodeficiency virus type 1 (HIV-1) vaccine. Some HIV-infected …